Peng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Chen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Zhi-Jun Jia
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China
7 shared publications Yongxiang Zheng
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy
5 shared publicationsXiao‐Qi Liu
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China
4 shared publicationsXin Wang
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Children’s Medicine Key Laboratory of Sichuan Province, Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital
3 shared publicationsYing Wu
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy
3 shared publicationsChun Zhang
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Department of Biopharmaceutics, West China School of Pharmacy Sichuan University Chengdu 610041 China
2 shared publications
Latest Publications
- Open Access
- 29 January 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (2) , 955-964
Reprogramming Imine Reductases for Enantioselective Reduction of Electron-Rich Enamides
Imine reductases (IREDs) are powerful biocatalysts to afford valuable enantioenriched amines via the stereoselective reduction of imines. While significant progress has been made in expanding their catalytic capabilities, direct reduction of electron-rich alkenes by IREDs remains a formidable challenge and is unprecedented in biology. Here, we report the reprogramming of an IRED from Sinorhizobium (SinIRED) to catalyze the enantioselective reduction of enamides. Through directed evolution, the final optimized SinIRED-V5 variant is able to reduce a variety of enamides and deliver diverse protected chiral amines in up to 97% yield and >99:1 enantiomeric ratio (e.r.). Mechanistic studies suggest a novel synergistic pathway involving enamine–imine tautomerization followed by NADPH-mediated hydride transfer process. This work expands the catalytic versatility of IREDs and provides the first known example of IRED-catalyzed reduction of electron-rich enamides.
- 29 January 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (2) , 955-964
Open AccessReprogramming Imine Reductases for Enantioselective Reduction of Electron-Rich Enamides
Imine reductases (IREDs) are powerful biocatalysts to afford valuable enantioenriched amines via the stereoselective reduction of imines. While significant progress has been made in expanding their catalytic capabilities, direct reduction of electron-rich alkenes by IREDs remains a formidable challenge and is unprecedented in biology. Here, we report the reprogramming of an IRED from Sinorhizobium (SinIRED) to catalyze the enantioselective reduction of enamides. Through directed evolution, the final optimized SinIRED-V5 variant is able to reduce a variety of enamides and deliver diverse protected chiral amines in up to 97% yield and >99:1 enantiomeric ratio (e.r.). Mechanistic studies suggest a novel synergistic pathway involving enamine–imine tautomerization followed by NADPH-mediated hydride transfer process. This work expands the catalytic versatility of IREDs and provides the first known example of IRED-catalyzed reduction of electron-rich enamides.
- Open Access
- 27 August 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4472-4480
Directed Evolution of Nonheme Iron Enzymes for Enantioselective Aminative Difunctionalization of Alkenes
The direct aminative difunctionalization of alkenes offers a powerful strategy for synthesizing valuable amine-containing compounds. However, achieving this transformation enantioselectively remains a significant challenge in both synthetic chemistry and biocatalysis. In this study, we engineered a nonheme iron enzyme, quercetin 2,3-dioxygenase from Bacillus subtilis (BsQueD), to catalyze three distinct alkene aminofunctionalization reactions with high efficiency and enantiocontrol. Through directed evolution, we developed an optimized BsQueD variant capable of producing a wide array of chiral 2-azidoamines, 2-aminothiazolines, and 2-aminooxazolines with up to 72% yield and 99:1 enantiomeric ratio (e.r.). Mechanistic investigations suggest a stepwise radical addition pathway. This work broadens the scope of biocatalytic alkene difunctionalization, providing a sustainable and efficient route for synthesizing diverse chiral primary amines.
- 27 August 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4472-4480
Open AccessDirected Evolution of Nonheme Iron Enzymes for Enantioselective Aminative Difunctionalization of Alkenes
The direct aminative difunctionalization of alkenes offers a powerful strategy for synthesizing valuable amine-containing compounds. However, achieving this transformation enantioselectively remains a significant challenge in both synthetic chemistry and biocatalysis. In this study, we engineered a nonheme iron enzyme, quercetin 2,3-dioxygenase from Bacillus subtilis (BsQueD), to catalyze three distinct alkene aminofunctionalization reactions with high efficiency and enantiocontrol. Through directed evolution, we developed an optimized BsQueD variant capable of producing a wide array of chiral 2-azidoamines, 2-aminothiazolines, and 2-aminooxazolines with up to 72% yield and 99:1 enantiomeric ratio (e.r.). Mechanistic investigations suggest a stepwise radical addition pathway. This work broadens the scope of biocatalytic alkene difunctionalization, providing a sustainable and efficient route for synthesizing diverse chiral primary amines.
- 29 June 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (34) , e202509359
Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters
Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.
- 29 June 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (34) , e202509359
Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters
Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.
- 29 June 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (34)
Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters
Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.
- 29 June 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (34)
Engineering Unspecific Peroxygenases for Enantioselective α‐Hydroxylation of β‐Ketoesters
Unspecific peroxygenases (UPOs) are promising biocatalysts for selective oxyfunctionalization. Compared to cytochrome P450 enzymes (P450s), the catalytic potential of UPOs has been less investigated, largely due to their limited natural diversity and the challenges associated with their optimization through enzyme engineering. In this study, we engineered an UPO from Aspergillus niger ( Ani UPO) to catalyze the enantioselective α‐hydroxylation of β‐ketoesters, a valuable transformation yet to be realized in biocatalysis. Through enzyme engineering, two Ani UPO variants, Ani UPO‐M3 and Ani UPO‐M6, were developed to produce a wide range of enantioenriched α‐hydroxy‐β‐ketoesters, achieving up to 97% yield, 4140 total turnover number (TTN), and >99:1 enantiomeric ratio (er). The biocatalytic process operates under mild conditions and is scalable for preparative applications. This study broadens the catalytic repertoire of UPOs and enhances their potential for industrial applications.
- 5 February 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (9)
Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme
Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.
- 5 February 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (9)
Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme
Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.
- 5 February 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (9) , e202423507
Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme
Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.
- 5 February 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (9) , e202423507
Enantioselective Trifluoromethylazidation of Styrenyl Olefins Catalyzed by an Engineered Nonheme Iron Enzyme
Organofluorines, particularly those containing trifluoromethyl (CF3) groups, play a critical role in medicinal chemistry. While trifluoromethylation of alkenes provides a powerful synthetic route to construct CF3‐containing compounds with broad structural and functional diversity, achieving enantioselective control in these reactions remains a formidable challenge. In this study, we engineered a nonheme iron enzyme, quercetin 2,3‐dioxygenase from Bacillus subtilis (BsQueD), for the enantioselective trifluoromethylazidation of alkenes. Through directed evolution, the final variant BsQueD‐CF3 exhibited excellent enantioselectivity, with an enantiomeric ratio (e.r.) of up to 98 : 2. Preliminary mechanistic studies suggest the involvement of radical intermediates. This work expands biocatalytic organofluorine chemistry by reprogramming metalloenzymes for innovative trifluoromethylation reactions.
- 28 August 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (36) , 24863-24870
Iron-Catalyzed Primary Amination of C(sp3)–H Bonds
Primary amines are privileged molecules in drug development. Yet, there is a noticeable scarcity of methods for directly introducing a primary amine group into the ubiquitous C(sp3)-H bonds within organic compounds. Here, we report an iron-based catalytic system that enables direct primary amination of C(sp3)-H bonds under aqueous conditions and air. Various types of C(sp3)-H bonds, including benzylic, allylic, and aliphatic ones, can be readily functionalized with high selectivity and efficiency. The broad utility of this method has been further verified by late-stage amination of 11 complex bioactive molecules. Mechanistic studies unveil a protonated iron-nitrene complex as the key intermediate for the C-H bond activation. This work extends the toolbox for direct C(sp3)-H functionalizations, opening up new opportunities for late-stage modifications of organic molecules.
- 28 August 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (36) , 24863-24870
Iron-Catalyzed Primary Amination of C(sp3)–H Bonds
Primary amines are privileged molecules in drug development. Yet, there is a noticeable scarcity of methods for directly introducing a primary amine group into the ubiquitous C(sp3)-H bonds within organic compounds. Here, we report an iron-based catalytic system that enables direct primary amination of C(sp3)-H bonds under aqueous conditions and air. Various types of C(sp3)-H bonds, including benzylic, allylic, and aliphatic ones, can be readily functionalized with high selectivity and efficiency. The broad utility of this method has been further verified by late-stage amination of 11 complex bioactive molecules. Mechanistic studies unveil a protonated iron-nitrene complex as the key intermediate for the C-H bond activation. This work extends the toolbox for direct C(sp3)-H functionalizations, opening up new opportunities for late-stage modifications of organic molecules.